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Background
Carbamylated allergoids are chemically modified extracts
developed to reduce the IgE binding activity and conse-
quently improve the SLIT tolerability. This study was
designed to compare the efficacy and safety of three
different daily dosages of carbamylated allergoid tablets
in patients allergic to ragweed pollen.
Methods
A prospective multicenter double-blind randomized
dose-ranging study (EudraCT number 2011-004522-10)
was conducted following GCP rules in patients with
history of ragweed-related moderate-to-severe allergic
rhinoconjunctivitis for at least 2 years, with or without
controlled seasonal allergic asthma, and positive
response to allergen specific nasal provocation test
(NPT). Before the 2013 ragweed pollen season adult
patients were assigned to different daily dosages (300-
1000-2000 UA) of tablets of ragweed pollen carbamylated
extract given for 4 months. The primary end-point was
the individual change in the response to NPT before and
after the treatment (allergic symptoms and threshold
provocative dose to identify improved, unchanged,
worsened subjects). Secondary end-points included the
analysis of this improvement considering the severity
level (depending on symptoms score and provocative
dose), the change of nasal peak inspiratory flow (NPIF) in
response to NPT, and the incidence of adverse events.
Results
Seventy-three subjects were enrolled and 52 were rando-
mized (1:1:1) and treated. The proportion of improved
patients was 77%, 88% and 81% in the 300 UA, 1000UA
and 2000 UA groups respectively. A progressive trend
to increased efficacy with flattening of the slope (mean
severity level improvement: +1.38, +1.71 and +1.90
respectively) and a statistically significant difference
between 300 UA and 2000 UA (p = 0.0187) were found.
NPIF improved in all groups at the end of the study
without significant differences among treatments (p =
0.41). One probable treatment-related AE occurred in
group 1, 3 probable and 1 certain (mild) in group 2, 3
possible and 1 certain (moderate) in group 3. No serious
treatment-related AEs occurred.
Conclusions
The three daily dosages provided improvement in the
response to the allergen specific NPT in a large proportion
of patients. The group receiving 1000 UA showed the
highest percentage of improved patients. The mean
improvement and the incidence of treatment-related AEs
suggest that this dosage appears to be the ideal dose of
carbamylated allergoid for treating ragweed pollen allergic
patients.
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